Blog Band - Page 8 of 312

Shots:The US FDA has granted 510(k) clearance to SyncAR Spine platform to enhance precision in spine surgerySyncAR Spine, integrated with Medtronic StealthStation, uses AI-driven vertebra segmentation, advanced decompression…

Oct 2025

NEWS

Arcus Biosciences Reports the P-II (EDGE-Gastric) Trial Data on Domvanalimab + Yutuo (Zimberelimab) for Gastroesophageal Adenocarcinomas

Shots:Arcus has reported data from Arm A1 (n=41) of the P-II (EDGE-Gastric) trial assessing domvanalimab (1600mg, IV, Q4W) + Yutuo (480mg, IV, Q4W) & CT in pts with locally…

Oct 2025

NEWS

Zoetis’ Lenivia (Izenivetmab) Receives the CVMP’s Recommendation for Osteoarthritis Pain Relief in Dogs

Shots:The CVMP has recommended Lenivia for the reduction of pain associated with osteoarthritis in dogs, with EC’s decision expected in Q4’25. Also, a commercial launch in the EU is…

Oct 2025

NEWS

BMS to Strengthen its Cell Therapy Portfolio with $1.5B Orbital Therapeutics Acquisition

Shots:BMS has entered into a definitive agreement to acquire Orbital, strengthening & diversifying its cell therapy portfolioAs per the deal, BMS will acquire Orbital, incl. its asset, OTX-201 &…

Oct 2025

NEWS

PharmaShots Weekly Snapshots (Oct 06, 2025 – Oct 10, 2025)  

This week, PharmaShots’ news was all about the updates on Clinical Trials, Regulatory, Pharma, MedTech, M&A, DigiHealth, Animal Health, and Biosimilars. Check out our full report below:   AstraZeneca and…

Oct 2025

VIDEO

LIFE SCIENCES | DAILY NEWS | OCT 10, 2025 | PHARMASHOTS

Oct 2025

NEWS

Adcendo’s ADCE-D01 Receives the US FDA’s Fast Track Designation to Treat Soft Tissue Sarcoma

Shots:The US FDA has granted FTD to ADCE-D01 for the treatment of soft tissue sarcoma (STS)ADCE-D01 is being evaluated in P-I/II (ADCElerate1/EUCT) dose escalation & expansion study as…

Oct 2025

NEWS

Ono Pharmaceutical Reports the P-II (ONO-4578-08) Trial Findings of ONO-4578 in Gastric or Gastroesophageal Junction (G/GEJ) Cancer

Shots:Ono Pharmaceutical has reported the P-II (ONO-4578-08) trial findings of ONO-4578 (EP4 antagonist) regimen for previously untreated, HER2-negative unresectable advanced or recurrent G/GEJ cancerONO-4578-08 assessed ONO-4578 (40mg, QD,…

Oct 2025

NEWS

Bio-Thera Collaborates with Intas Pharmaceuticals for the Commercialization of BAT2506 (Biosimilar, Simponi) Across Canada

Shots:Bio-Thera Solutions has entered into an exclusive commercialization & license agreement with Intas Pharmaceuticals for BAT2506, a biosimilar version of Simponi (golimumab), for CanadaThe agreement expands their Feb 2025…

Oct 2025

NEWS

Phibro Animal Health Collaborates with Lighthouse Pharmaceuticals for Novel Canine Periodontal Therapy

Shots:Phibro Animal Health has entered into a licensing agreement with Lighthouse Pharmaceuticals to develop & commercialize a therapeutic asset targeting periodontal health in companion animalsAs per the agreement,…

Surgical Theater’s SyncAR Spine Platform Secures the US FDA’s 510(k) Clearance for Spine Surgery

Arcus Biosciences Reports the P-II (EDGE-Gastric) Trial Data on Domvanalimab + Yutuo (Zimberelimab) for Gastroesophageal Adenocarcinomas

Zoetis’ Lenivia (Izenivetmab) Receives the CVMP’s Recommendation for Osteoarthritis Pain Relief in Dogs

BMS to Strengthen its Cell Therapy Portfolio with $1.5B Orbital Therapeutics Acquisition

PharmaShots Weekly Snapshots (Oct 06, 2025 – Oct 10, 2025)

LIFE SCIENCES | DAILY NEWS | OCT 10, 2025 | PHARMASHOTS

Adcendo’s ADCE-D01 Receives the US FDA’s Fast Track Designation to Treat Soft Tissue Sarcoma

Ono Pharmaceutical Reports the P-II (ONO-4578-08) Trial Findings of ONO-4578 in Gastric or Gastroesophageal Junction (G/GEJ) Cancer

Bio-Thera Collaborates with Intas Pharmaceuticals for the Commercialization of BAT2506 (Biosimilar, Simponi) Across Canada

Phibro Animal Health Collaborates with Lighthouse Pharmaceuticals for Novel Canine Periodontal Therapy

Contact US

OUR INFORMATION

FOLLOW US